These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11574200)

  • 1. Evaluation of the safety of macrolides.
    Williams JD
    Int J Antimicrob Agents; 2001; 18 Suppl 1():S77-81. PubMed ID: 11574200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fourteen-membered ring macrolides as anti-angiogenic compounds.
    Yatsunami J; Hayashi S
    Anticancer Res; 2001; 21(6B):4253-8. PubMed ID: 11908678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ketolides: a critical review.
    Zhanel GG; Walters M; Noreddin A; Vercaigne LM; Wierzbowski A; Embil JM; Gin AS; Douthwaite S; Hoban DJ
    Drugs; 2002; 62(12):1771-804. PubMed ID: 12149046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative safety of the different macrolides.
    Rubinstein E
    Int J Antimicrob Agents; 2001; 18 Suppl 1():S71-6. PubMed ID: 11574199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of macrolides and ketolides: focus on respiratory tract infections.
    Zhanel GG; Dueck M; Hoban DJ; Vercaigne LM; Embil JM; Gin AS; Karlowsky JA
    Drugs; 2001; 61(4):443-98. PubMed ID: 11324679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrolide therapy of pneumonia: is it necessary, and how does it help?
    Restrepo MI; Sole-Violan J; Martin-Loeches I
    Curr Opin Infect Dis; 2016 Apr; 29(2):212-7. PubMed ID: 26836375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Macrolides today. Their extensive use in daily practice is justified].
    Portier H; Chavanet P
    Rev Prat; 1991 Oct; 41(21):2065-7. PubMed ID: 1784900
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse effects of macrolide antibacterials.
    Periti P; Mazzei T; Mini E; Novelli A
    Drug Saf; 1993 Nov; 9(5):346-64. PubMed ID: 8280403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of macrolides in the treatment of outpatient pneumonia].
    Sinopal'nikov AI; Fesenko OV
    Klin Med (Mosk); 1997; 75(6):46-50. PubMed ID: 9273402
    [No Abstract]   [Full Text] [Related]  

  • 10. New treatment options for lower respiratory tract infections.
    Kocsis B; Szabo D
    Expert Opin Pharmacother; 2017 Sep; 18(13):1345-1355. PubMed ID: 28762839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory activity of macrolides: a new therapeutic potential?
    Labro MT
    J Antimicrob Chemother; 1998 Mar; 41 Suppl B():37-46. PubMed ID: 9579711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial macrolides: a drug class with a complex pharmacological profile.
    Abu-Gharbieh E; Vasina V; Poluzzi E; De Ponti F
    Pharmacol Res; 2004 Sep; 50(3):211-22. PubMed ID: 15225662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.
    Principi N; Esposito S
    Drug Saf; 1999 Jan; 20(1):25-41. PubMed ID: 9935275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials.
    Zhuo GY; He Q; Xiang-Lian L; Ya-Nan Y; Si-Te F
    Pulm Pharmacol Ther; 2014 Oct; 29(1):80-8. PubMed ID: 24594263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review.
    Cai Y; Chai D; Wang R; Bai N; Liang BB; Liu Y
    J Antimicrob Chemother; 2011 May; 66(5):968-78. PubMed ID: 21393178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials.
    Skalsky K; Yahav D; Lador A; Eliakim-Raz N; Leibovici L; Paul M
    Clin Microbiol Infect; 2013 Apr; 19(4):370-8. PubMed ID: 22489673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrolides in community-acquired pneumonia: does the bell toll for thee?
    Granowitz EV; Brown RB
    Chest; 2005 Sep; 128(3):1089-93. PubMed ID: 16162689
    [No Abstract]   [Full Text] [Related]  

  • 20. Telithromycin: new preparation. A needless addition to the other macrolides.
    Prescrire Int; 2003 Feb; 12(63):8-11. PubMed ID: 12602373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.